Carnitine metabolisme, excretie, deficiëntie, interactie met chemotherapie (oxaliplatin) Deficiency/lack of/reduction of concentration of carnitine (an amino acid or half-vitamin) during/caused by treatment with chemotherapy (oxaliplatin)
Conditions
Interventions
Patients will receive levocarnitine 2 gram intravenously, before start of the
oxaliplatin-based chemotherapy. Blood and urinary samples will be collected
during administration of the chemotherapy.
Sponsors
Maxima Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Written informed consent 2. Age >18 years 3. Start treatment with oxaliplatin-based chemotherapy 4. Understanding the Dutch language
Exclusion criteria
Exclusion criteria: 1. No written informed consent 2. Patients with known primary carnitine deficiency (congenital) 3. Patients on haemodialysis or peritoneal dialysis 4. Patients with epilepsy 5. Current treatment with valproic acid or zidovudine 6. Current use of carnitine supplements or use of carnitine supplements in the past 3 months 7. Pre-existent neuropathy or comorbid disorder causing neuropathy 8. Previous treatment with neurotoxic chemotherapy 9. Participation in an intervention study on CIPN (e.g. Frozen Gloves) 6. Current use of carnitine supplements or use of carnitine supplements in the past 3 months, 7. Pre-existent neuropathy or comorbid disorder causing neuropathy, 8. Previous treatment with neurotoxic chemotherapy, 9. Participation in an intervention study on CIPN (e.g. Frozen Gloves)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The entire carnitine spectrum in plasma will be measured using a precursor ion scan. Urinary analysis will be done to measure the concentration of L-carnitine in urine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicable. | — |
Countries
Netherlands
Outcome results
None listed